Gastrointestinal and liver conditions treated with drugs affecting the immune response [NG172], NICE (updated 21st August 2020)

The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. 21 August 2020: We updated recommendations in section 4 on delivering planned care in line with our guideline on arranging planned care in hospitals and diagnostic services, and linked to British Society of Gastroenterology guidance on restarting gastrointestinal endoscopy. Minor ch anges since publication 7 July 2020: We changed the wording of the links in recommendation 2.5 to match the titles of the specialist guidance.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news